IMV Inc IMVIF

RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

[PoorOpinion]

TexasTea20 wrote: As much as I think it would help liquidity, valuation etc.., I disagree that IMV should do a financing now. This is not the time. They are cashed up thru 2019 and I am sure have the relationships in place to pull the trigger on "a" financing anythime....but they are likely more interested in the "right" time. Based on IMV's stated milestones I would suggest a financing only gets done around or in conjunction with their meeting with the FDA on breakthrough status and the FDA's reply in Q2 of 2019. That is the kind of announcement that get's the interest of the investing world. I have resigned myself that IMV will not make the big valution leap (10x +) until that point.
Just my opionion.

I agree the fda meeting is maybe more exciting than the Dec 14th reveal of the detailed data in terms of moving the stock.

Anybody have any thoughts on the prolonged nature of the patients response in the subset group? It was emphasised several times but not went into in detail, ie how this compares with other treatments. The subset group is n=5, so rather small, does the prolonged response add significant weight?